
June 30 (Reuters) - Moderna Inc MRNA.O:
MODERNA - ANNOUNCES POSITIVE PHASE 3 RESULTS FOR SEASONAL INFLUENZA VACCINE
MODERNA - MRNA-1010 ACHIEVED STRINGENT SUPERIORITY CRITERION PRESPECIFIED IN THE PROTOCOL, WITH AN RVE OF 26.6% IN OVERALL STUDY POPULATION
MODERNA - IN PARTICIPANTS AGED 65 YEARS AND OLDER, MRNA-1010 DEMONSTRATED AN RVE OF 27.4%
MODERNA - SAFETY AND TOLERABILITY OF MRNA-1010 WERE CONSISTENT WITH REPORTED RESULTS FROM A PREVIOUS PHASE 3 STUDY.
MODERNA - STRONG RVE WAS OBSERVED FOR EACH INFLUENZA STRAIN CONTAINED IN THE VACCINE DURING STUDY